Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
AssigneeSt. Jude Children's Research Hospital
InventorsJulia L. Hurwitz, Randall J. Owens
Life of this patent
Estimating the term…
Abstract
Polyenv vaccines are provided that comprise mixtures of at least 4-40 to about 10,000 different recombinant vaccinia viruses that each express a different HIV env variant or a portion thereof containing both constant and variable regions, as well as methods of making and using such polyenv vaccines and vaccinia viruses, including the use of the polyenv vaccine, in live, attenuated or inactivated form, for prophylaxis or treatment of HIV infection.
Claims18
An immunogenic composition that can elicit an immune response to more than one but not necessarily all of the env variants contained in the composition, comprising at least 4 to about 10,000 recombinant vaccinia viruses, each comprising an env variant (EV) nucleotide encoding a different envelope protein variant of a human immunodeficiency virus (HIV), wherein
- (i) said EV nucleotide encodes both variable and constant regions of said envelope protein variant;
- and
- (ii) said immunogenic composition is capable of eliciting at least one of a cellular and a humoral immmune response in a mammal against an HIV strain.
A method for making a immunogenic composition that can elicit an immune response to more than one but not necessarily all of the env variants contained in the composition, comprising combining in admixture at least 4 to about 10,000 recombinant viruses to obtain a immunogenic composition, wherein
- (i) each of said recombinant viruses comprises an env variant (EV) nucleotide encoding a different envelope protein variant of an HIV envelope protein;
- (ii) said EV nucleotide encodes both variable and constant regions of said envelope protein variant;
- and
- (iii) said immunogenic composition is capable of eliciting at least one of a cellular and a humoral immune response in a mammal against an HIV strain.
A method for eliciting a humoral or cellular immune response, or both, to a human immunodeficiency virus (HIV) in a mammal, comprising
- administering to said mammal an effective amount of a immunogenic composition comprising at least 4 to about 10,000 different recombinant viruses, wherein
- (i) each of said recombinant viruses comprises an env variant (EV) nucleotide encoding a different envelope protein variant of an HIV envelope protein;
- (ii) said EV nucleotide encodes both variable and constant regions of said envelope protein variant;
- and
- (iii) said amount of said immunogenic composition is effective to elicit at least one of a cellular and a humoral immune response in said mammal against an HIV strain infecting said mammal.
Dependencies are inferred from the claim text.